Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antiparasitic Agents | 2 | 2021 | 267 | 1.45 | Why? |
| Frailty | 4 | 2021 | 1432 | 1.17 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 520 | 1.13 | Why? |
| Metformin | 3 | 2020 | 640 | 1.04 | Why? |
| Pharmaceutical Preparations | 4 | 2021 | 1897 | 0.97 | Why? |
| Ivermectin | 2 | 2021 | 973 | 0.90 | Why? |
| Prochlorperazine | 1 | 2020 | 7 | 0.90 | Why? |
| Venous Thrombosis | 3 | 2021 | 2739 | 0.86 | Why? |
| Amiodarone | 1 | 2022 | 110 | 0.85 | Why? |
| Antiemetics | 1 | 2020 | 75 | 0.82 | Why? |
| Platelet Aggregation Inhibitors | 2 | 2021 | 1671 | 0.81 | Why? |
| Renin-Angiotensin System | 6 | 2021 | 3661 | 0.80 | Why? |
| Panic Disorder | 1 | 2020 | 84 | 0.79 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 350 | 0.78 | Why? |
| Strongyloidiasis | 1 | 2020 | 80 | 0.78 | Why? |
| Venous Thromboembolism | 4 | 2021 | 4273 | 0.76 | Why? |
| Laryngopharyngeal Reflux | 1 | 2020 | 78 | 0.74 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 1510 | 0.73 | Why? |
| Famotidine | 1 | 2021 | 136 | 0.73 | Why? |
| Whooping Cough | 1 | 2020 | 201 | 0.71 | Why? |
| Nausea | 1 | 2020 | 457 | 0.67 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2021 | 5277 | 0.66 | Why? |
| Observational Studies as Topic | 3 | 2021 | 1887 | 0.66 | Why? |
| Macrolides | 1 | 2020 | 369 | 0.66 | Why? |
| Warfarin | 2 | 2020 | 402 | 0.64 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2020 | 436 | 0.63 | Why? |
| Intracranial Thrombosis | 1 | 2021 | 339 | 0.62 | Why? |
| Chemoprevention | 1 | 2021 | 585 | 0.61 | Why? |
| Anticoagulants | 7 | 2021 | 9563 | 0.61 | Why? |
| Vomiting | 1 | 2020 | 722 | 0.59 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2020 | 694 | 0.59 | Why? |
| Azithromycin | 2 | 2020 | 3943 | 0.58 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.56 | Why? |
| Alanine | 3 | 2021 | 5687 | 0.56 | Why? |
| Overweight | 1 | 2020 | 916 | 0.54 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 1454 | 0.54 | Why? |
| Takotsubo Cardiomyopathy | 1 | 2020 | 453 | 0.53 | Why? |
| Randomized Controlled Trials as Topic | 7 | 2021 | 10649 | 0.53 | Why? |
| Migraine Disorders | 1 | 2020 | 530 | 0.51 | Why? |
| Melatonin | 1 | 2020 | 578 | 0.50 | Why? |
| Humans | 83 | 2022 | 930598 | 0.50 | Why? |
| Pandemics | 31 | 2021 | 389249 | 0.50 | Why? |
| Rhinitis, Allergic | 1 | 2020 | 704 | 0.50 | Why? |
| Aspirin | 1 | 2021 | 1043 | 0.49 | Why? |
| Angiotensin Receptor Antagonists | 4 | 2021 | 3892 | 0.48 | Why? |
| Hyperglycemia | 2 | 2021 | 1363 | 0.44 | Why? |
| Diabetes Mellitus, Type 2 | 3 | 2021 | 6166 | 0.44 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.43 | Why? |
| Blood Coagulation | 2 | 2020 | 2768 | 0.42 | Why? |
| Acute Kidney Injury | 2 | 2021 | 5762 | 0.41 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.41 | Why? |
| Obesity, Morbid | 1 | 2021 | 1340 | 0.40 | Why? |
| Pneumonia, Viral | 17 | 2020 | 243684 | 0.38 | Why? |
| Coronavirus Infections | 17 | 2020 | 253789 | 0.37 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.37 | Why? |
| Epilepsy | 1 | 2021 | 1401 | 0.36 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.36 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.35 | Why? |
| Betacoronavirus | 16 | 2020 | 204454 | 0.34 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.34 | Why? |
| Coronavirus | 3 | 2021 | 18339 | 0.33 | Why? |
| Frail Elderly | 4 | 2021 | 1427 | 0.32 | Why? |
| Acute Coronary Syndrome | 1 | 2020 | 2107 | 0.32 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 3832 | 0.31 | Why? |
| Weight Gain | 2 | 2020 | 552 | 0.29 | Why? |
| Medication Therapy Management | 2 | 2020 | 312 | 0.29 | Why? |
| Cardiology | 1 | 2020 | 2873 | 0.29 | Why? |
| Cardiovascular Diseases | 2 | 2020 | 11497 | 0.29 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.28 | Why? |
| Asthma | 2 | 2020 | 4383 | 0.28 | Why? |
| Rheumatic Diseases | 1 | 2020 | 2675 | 0.28 | Why? |
| Adrenal Cortex Hormones | 5 | 2021 | 6537 | 0.27 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.27 | Why? |
| Inappropriate Prescribing | 2 | 2017 | 284 | 0.27 | Why? |
| Drug Administration Routes | 2 | 2021 | 106 | 0.27 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2020 | 3051 | 0.26 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.26 | Why? |
| Antihypertensive Agents | 3 | 2020 | 1962 | 0.26 | Why? |
| Research Design | 1 | 2020 | 5830 | 0.26 | Why? |
| Percutaneous Coronary Intervention | 1 | 2020 | 3646 | 0.26 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.25 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.24 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.23 | Why? |
| Insulin | 2 | 2021 | 1316 | 0.23 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.22 | Why? |
| Contraceptives, Oral, Hormonal | 1 | 2020 | 42 | 0.21 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.21 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.21 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.21 | Why? |
| Histamine H2 Antagonists | 1 | 2021 | 111 | 0.20 | Why? |
| Drug Costs | 2 | 2021 | 313 | 0.20 | Why? |
| Ultrasonography, Doppler, Duplex | 1 | 2021 | 168 | 0.20 | Why? |
| Biological Availability | 1 | 2021 | 388 | 0.20 | Why? |
| Sulfides | 1 | 2020 | 113 | 0.20 | Why? |
| Angiotensins | 1 | 2020 | 259 | 0.19 | Why? |
| Sample Size | 1 | 2021 | 518 | 0.19 | Why? |
| Acetates | 1 | 2020 | 123 | 0.19 | Why? |
| Homes for the Aged | 3 | 2017 | 1071 | 0.19 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.18 | Why? |
| Preliminary Data | 1 | 2020 | 457 | 0.18 | Why? |
| Infarction | 1 | 2020 | 206 | 0.18 | Why? |
| Hepatitis, Viral, Human | 1 | 2021 | 196 | 0.18 | Why? |
| Cyclopropanes | 1 | 2020 | 332 | 0.18 | Why? |
| Central Nervous System Agents | 1 | 2017 | 45 | 0.17 | Why? |
| Polypharmacy | 2 | 2017 | 347 | 0.17 | Why? |
| Hypoglycemic Agents | 2 | 2020 | 2165 | 0.17 | Why? |
| Costs and Cost Analysis | 2 | 2021 | 694 | 0.17 | Why? |
| Heparin | 2 | 2021 | 2600 | 0.17 | Why? |
| Contraception | 1 | 2020 | 291 | 0.17 | Why? |
| Drug and Narcotic Control | 1 | 2018 | 134 | 0.16 | Why? |
| Pancreas | 1 | 2020 | 398 | 0.16 | Why? |
| Methotrexate | 1 | 2021 | 471 | 0.16 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.16 | Why? |
| Quinolines | 1 | 2020 | 403 | 0.15 | Why? |
| Glucocorticoids | 3 | 2021 | 4431 | 0.15 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.15 | Why? |
| Antidepressive Agents | 1 | 2021 | 509 | 0.15 | Why? |
| Proton Pump Inhibitors | 1 | 2020 | 377 | 0.15 | Why? |
| Anticonvulsants | 1 | 2021 | 634 | 0.15 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.15 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.15 | Why? |
| Living Donors | 1 | 2020 | 652 | 0.14 | Why? |
| Pharmacies | 1 | 2020 | 356 | 0.14 | Why? |
| Quality Indicators, Health Care | 1 | 2020 | 580 | 0.14 | Why? |
| Circadian Rhythm | 1 | 2021 | 607 | 0.14 | Why? |
| Inpatients | 2 | 2021 | 5161 | 0.14 | Why? |
| Immunoglobulins | 1 | 2020 | 811 | 0.14 | Why? |
| Antithrombins | 1 | 2018 | 353 | 0.14 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.13 | Why? |
| Colchicine | 1 | 2021 | 730 | 0.13 | Why? |
| Critical Illness | 4 | 2021 | 17281 | 0.13 | Why? |
| Drug Interactions | 1 | 2021 | 1653 | 0.13 | Why? |
| Risk Assessment | 4 | 2021 | 25439 | 0.13 | Why? |
| Factor Xa Inhibitors | 1 | 2018 | 490 | 0.12 | Why? |
| Risk Management | 1 | 2020 | 1044 | 0.12 | Why? |
| Rats | 1 | 2020 | 2764 | 0.12 | Why? |
| Dexamethasone | 2 | 2021 | 2055 | 0.12 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.12 | Why? |
| Patients | 1 | 2020 | 1167 | 0.12 | Why? |
| Rituximab | 1 | 2020 | 1096 | 0.12 | Why? |
| Drug Prescriptions | 1 | 2021 | 1062 | 0.12 | Why? |
| Drug Monitoring | 1 | 2020 | 1408 | 0.12 | Why? |
| Taiwan | 1 | 2020 | 2556 | 0.12 | Why? |
| Pharmaceutical Services | 1 | 2017 | 347 | 0.12 | Why? |
| Immunomodulation | 1 | 2021 | 1472 | 0.12 | Why? |
| Nursing Homes | 3 | 2017 | 4155 | 0.12 | Why? |
| Pharmacists | 2 | 2020 | 1246 | 0.10 | Why? |
| Methylprednisolone | 1 | 2021 | 2107 | 0.10 | Why? |
| Headache | 1 | 2020 | 2257 | 0.10 | Why? |
| Fatigue | 1 | 2021 | 2479 | 0.10 | Why? |
| Malaysia | 3 | 2018 | 1116 | 0.09 | Why? |
| Fibrinolytic Agents | 1 | 2020 | 1702 | 0.09 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.09 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.09 | Why? |
| Risk | 1 | 2021 | 5288 | 0.09 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.09 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.09 | Why? |
| Sleep | 1 | 2021 | 2695 | 0.09 | Why? |
| Dietary Supplements | 1 | 2020 | 2251 | 0.09 | Why? |
| Survival Analysis | 1 | 2021 | 7592 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| Arrhythmias, Cardiac | 1 | 2021 | 2510 | 0.08 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.08 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.08 | Why? |
| Echocardiography | 1 | 2020 | 3661 | 0.08 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.08 | Why? |
| Patient Selection | 1 | 2021 | 4560 | 0.08 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2020 | 1969 | 0.08 | Why? |
| Italy | 2 | 2020 | 38444 | 0.08 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.07 | Why? |
| Vitamin D | 1 | 2020 | 2904 | 0.07 | Why? |
| United Kingdom | 2 | 2021 | 18046 | 0.07 | Why? |
| Pakistan | 2 | 2021 | 2302 | 0.06 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.06 | Why? |
| Spain | 1 | 2021 | 15545 | 0.06 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.06 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.06 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.06 | Why? |
| Aged | 8 | 2021 | 215776 | 0.05 | Why? |
| Thiazolidinediones | 1 | 2020 | 70 | 0.05 | Why? |
| Mice | 1 | 2020 | 21357 | 0.05 | Why? |
| Incretins | 1 | 2020 | 61 | 0.05 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.05 | Why? |
| Cardiac Electrophysiology | 1 | 2021 | 239 | 0.05 | Why? |
| Deprescriptions | 1 | 2020 | 294 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.05 | Why? |
| Potentially Inappropriate Medication List | 1 | 2017 | 55 | 0.04 | Why? |
| Cost-Benefit Analysis | 2 | 2018 | 2259 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2021 | 782 | 0.04 | Why? |
| Electrophysiologic Techniques, Cardiac | 1 | 2021 | 396 | 0.04 | Why? |
| China | 2 | 2020 | 50654 | 0.04 | Why? |
| Africa South of the Sahara | 1 | 2021 | 1335 | 0.04 | Why? |
| Patient Care Planning | 1 | 2020 | 582 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.04 | Why? |
| Cost Savings | 1 | 2017 | 296 | 0.04 | Why? |
| Female | 6 | 2021 | 380317 | 0.04 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.03 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.03 | Why? |
| New Zealand | 1 | 2018 | 2073 | 0.03 | Why? |
| Health Care Surveys | 1 | 2021 | 2942 | 0.03 | Why? |
| Child | 1 | 2020 | 70012 | 0.03 | Why? |
| Animals | 1 | 2020 | 78931 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Monitoring, Physiologic | 1 | 2020 | 1956 | 0.02 | Why? |
| England | 1 | 2021 | 5116 | 0.02 | Why? |
| Male | 5 | 2021 | 367725 | 0.02 | Why? |
| Professional Role | 1 | 2017 | 1280 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.02 | Why? |
| Guideline Adherence | 1 | 2020 | 2309 | 0.02 | Why? |
| Blood Glucose | 1 | 2020 | 3642 | 0.02 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.02 | Why? |
| Republic of Korea | 1 | 2018 | 5858 | 0.02 | Why? |
| Australia | 1 | 2018 | 6306 | 0.02 | Why? |
| Thromboembolism | 1 | 2018 | 2101 | 0.02 | Why? |
| Healthcare Disparities | 1 | 2021 | 3893 | 0.02 | Why? |
| Practice Patterns, Physicians' | 1 | 2021 | 4927 | 0.01 | Why? |
| India | 1 | 2018 | 11875 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2017 | 88759 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Depression | 1 | 2021 | 14116 | 0.01 | Why? |
| Middle Aged | 2 | 2021 | 270681 | 0.01 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.01 | Why? |
| Adult | 1 | 2021 | 244371 | 0.00 | Why? |